ReviewImmunological reviews2026
Inflammation-Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity.
Review in Immunological reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lymphoid structures (LS) arising in nonlymphoid tissues are increasingly recognized as active immune niches rather than simple consequences of chronic inflammation. In this review, we propose a framework that distinguishes inflammatory lymphoid structures (ILS) from mature tertiary lymphoid structures (mTLS), while acknowledging that these entities may form a continuum in some settings and represent distinct inflammatory states in others. We discuss how LS develop across autoimmunity, cancer, transplantation, immune-related adverse events, and aging, and how differences in architecture, stromal organization, antigen persistence, and tolerance checkpoints shape their biological outputs. Whereas mTLS are typically associated with follicular organization, germinal center-like reactions, and local clonal diversification, ILS may instead sustain inflammation through extrafollicular activation, survival niche formation, and tissue-adapted immune specialization. Importantly, the functional impact of LS is highly context dependent: they may promote pathogenic autoreactivity in autoimmune disease, support protective antitumor immunity in cancer, or acquire regulatory or suppressive features depending on the microenvironment. We also review current therapeutic strategies targeting LS and discuss how spatial transcriptomics and artificial intelligence may refine their detection, classification, and functional interpretation. Altogether, this perspective supports viewing LS as heterogeneous tissue immune niches rather than a binary TLS category, with major implications for pathogenesis, biomarker development, and therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.